Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

ARIAD Announces Appointments of Key Members of Leadership Team

Published: Friday, February 22, 2013
Last Updated: Friday, February 22, 2013
Bookmark and Share
Ready for anticipated regulatory approval and launch of Iclusig® in Europe this year.

ARIAD Pharmaceuticals, Inc. announced the appointment of Jonathan E. Dickinson to the position of General Manager, ARIAD Pharmaceuticals (Europe), Sàrl. Mr. Dickinson is a seasoned commercial executive bringing more than 20 years of pharmaceutical-industry experience to ARIAD, with special emphasis on global and pan-European leadership of several important cancer medicines. Mr. Dickinson is responsible for leading ARIAD’s European commercialization initiatives -- focused first on the anticipated European approval and launch of Iclusig® (ponatinib) in the third quarter of 2013 and subsequently on ARIAD’s other cancer medicines in development.

Mr. Dickinson joined ARIAD from Bristol-Myers Squibb, where he served for the past three years as the European brand lead for ipilimumab, responsible for the product’s European launch and commercialization in 29 countries. Previously, during his 13-year tenure at Hoffmann-La Roche, Mr. Dickinson held several key leadership positions, including lifecycle leader for capecitabine, where he managed global marketing, clinical development, regulatory affairs and manufacturing activities for the brand. At Roche, he had assignments both in the U.S. and Switzerland that included leadership roles of Roche’s three leading oncology medicines -- trastuzumab, rituximab, and capecitabine. Mr. Dickinson began his career at Novartis, where he held commercial roles in its oncology and endocrinology businesses, including medical sales, product manager and business director in the United Kingdom.

Mr. Dickinson received his B.Sc. degree in Genetics and his M.B.A. degree from the University of Nottingham. He is based at ARIAD’s European headquarters in Lausanne, Switzerland and reports to Marty J. Duvall, senior vice president, commercial operations of ARIAD.

“Jonathan is a proven leader with broad commercial and general management experience promoting several of the most highly regarded oncology medicines available today,” stated Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD. “His knowledge of the evolving European market and his success in commercializing important cancer medicines throughout Europe and globally will serve us well as we prepare for anticipated approval and commercialization of Iclusig in the EU this year.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

ARIAD Presents Data for Investigational Inhibitor
New preclinical data showing AP26113 inhibits clinically relevant mutants of ALK and ROS1.
Thursday, April 11, 2013
New Study by ARIAD Scientists Offers Insights into Design of Small-Molecule Drugs to Treat Drug-Resistant Leukemia
ARIAD publishes the high-resolution structure of the protein responsible for a major clinically relevant genetic variant of drug-resistant chronic myeloid leukemia.
Wednesday, October 10, 2007
Scientific News
Gene Therapy for Metabolic Liver Diseases
Researchers have tested gene therapy in pigs from hereditary tyrosinemia type 1, with corrected liver cells being transplanted into the diseased liver.
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
Gene-Editing 'Toolbox' Targets Multiple Genes Simultaneously
Researchers have designed a system that modifies, or edits, multiple genes in a genome at once while minimising unintentional effects.
Discovering the First Farmers
Genetic analyses reveal a collection of highly distinct groups in the Near East and Europe at the dawn of agriculture.
Fighting Cancer Through Protein Pathways
Researchers have found a new drug target within a protein production pathway critical to regulating growth and proliferation of cells.
Mutations in DNA-Repair Genes Found in Advanced Prostate Cancers
New findings indicate that nearly 12% of male advanced prostate cancer sufferers have inherited mutation in DNA-repair genes.
Ice Bucket Challenge Instrumental in Gene Discovery
Donations from the ALS Ice Bucket Chellenge allowed for the largest-ever study of inherited ALS, which identified a new ALS gene.
Triple-Action Therapy Patch Shows Promise
Patch that delivers drug, gene, and light-based therapy to tumor sites shows promising results in mice.
Cancer Gene-Drug Combinations Ripe for Precision Medicine
The study aims to expand the number of cancer gene mutations that can be paired with a precision therapy.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!